CN107432904A - A kind of hypoglycemic composition and preparation method thereof, application - Google Patents
A kind of hypoglycemic composition and preparation method thereof, application Download PDFInfo
- Publication number
- CN107432904A CN107432904A CN201610371196.4A CN201610371196A CN107432904A CN 107432904 A CN107432904 A CN 107432904A CN 201610371196 A CN201610371196 A CN 201610371196A CN 107432904 A CN107432904 A CN 107432904A
- Authority
- CN
- China
- Prior art keywords
- grape
- oil
- onion
- group
- kernel oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract description 35
- 239000001068 allium cepa oil Substances 0.000 claims abstract description 49
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 16
- 239000002131 composite material Substances 0.000 claims abstract description 14
- 241000234282 Allium Species 0.000 claims abstract description 13
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 13
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 13
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 13
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 13
- 240000006365 Vitis vinifera Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 7
- 238000001256 steam distillation Methods 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000036541 health Effects 0.000 abstract description 5
- 239000000314 lubricant Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000004519 grease Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 33
- 241000700159 Rattus Species 0.000 description 23
- 239000008103 glucose Substances 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 229920002527 Glycogen Polymers 0.000 description 17
- 229940096919 glycogen Drugs 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 241000219095 Vitis Species 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 230000024704 B cell apoptotic process Effects 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 241000218989 Trichosanthes Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- -1 propylhomoserin sulfoxide Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 241001506304 Kadsura japonica Species 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 1
- 235000015295 alliin Nutrition 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- RRVPUUKXVMZYMK-UHFFFAOYSA-N butanoic acid sulfonylurea Chemical group CCCC(O)=O.NC(=O)N=S(=O)=O RRVPUUKXVMZYMK-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
- C11B1/04—Pretreatment of vegetable raw material
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/06—Production of fats or fatty oils from raw materials by pressing
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/12—Production of fats or fatty oils from raw materials by melting out
- C11B1/16—Production of fats or fatty oils from raw materials by melting out with steam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to technical field of health care food, more particularly to a kind of hypoglycemic composition and preparation method thereof, application.The vegetable fat composite includes onion oil and grape-kernel oil.Onion oil and grape-kernel oil are used cooperatively by the present invention, and onion oil can play synergy with each lubricant component of grape-kernel oil, and so as to reach more preferable hypoglycemic effect, effect is better than the effect that onion oil or grape-kernel oil are used alone；Also, onion oil and grape-kernel oil can medicine-food two-purpose, have no side effect；Meanwhile the simple science of preparation method of the present invention, onion and grease effective constituents in grape pip can be sufficiently reserved.
Description
Technical field
The present invention relates to technical field of health care food, more particularly to a kind of hypoglycemic composition and its preparation side
Method, application.
Background technology
Diabetes are a kind of chronic metabolic diseases, are divided to primary and the major class of Secondary cases two.Because internal pancreas
Island element secretion definitely deficiency and relative deficiency, cause sugar, fat, protein metabolism disorderly, mainly sugar
Catabolism obstacle, produces a large amount of mesostates, such as ketoboidies, and mesostate causes many
Serious acute, chronic complication, these complication have a strong impact on the life and health of diabetic,
It is the main reason for causing the high case fatality rate of diabetes and high disability rate.Data show that China's diabetes are ill
Rate increases rapidly, just has a people to suffer from diabetes in average every 10 adults, rejuvenation trend is obvious.
If the World Health Organization, it is expected that do not take action as early as possible, to the year two thousand forty, the diabetic of China will increase
It is added to 1.5 hundred million people.
At present, treating the oral drugs of diabetes mainly includes
(1) sulfonylurea drugs
Hypoglycemic mechanism mainly stimulates insulin secretion, to there is certain islet function person curative effect preferable.But deposit
In a series of contraindication：First, serious Liver and kidney function is not complete；Second, severe infection, wound and
During major operation, insulin therapy is used instead temporarily；Third, during Diabetic ketosis, DKA, face
Shi Gaiyong insulin therapies；Fourth, pregnant diabetic women, pregnant hyperglycaemia has the effect of teratogenesis shape to fetus, early
Production, stillbirth incidence are high；Fifth, to sulfonylurea drugs allergy or there is obvious adverse reaction.
(2) biguanides
Hypoglycemic main mechanism is the utilization for increasing peripheral tissues to glucose, increases the anaerobic of glucose
Glycolysis, absorption of the intestines and stomach to glucose is reduced, is lost weight.Contraindication includes：Serious liver, kidney,
The heart, lung disease, deeline is malnutritive, ischemic disease；Diabetic ketosis, in ketosis acid
Poison；It stress suspend biguanides during situation with severe infections, operation, wound etc., use insulin instead
Treatment；The gestational period.Common adverse reactions include：1. gastrointestinal reaction, show as Nausea and vomiting, appetite
Decline, stomachache, diarrhoea, incidence is up to 20%；2. headache, dizzy, metallic taste；3. lactic acidosis,
Long-term, extensive application phenformin is more common in, is declined with Liver and kidney function, ischemic disease, acute sense
When dye, enterogastric diseases, melbine causes the chance of acid poisoning less.
(3) α glucosidase inhibitors
1 type and diabetes B can be used, and main adverse reaction has：Stomachache, intestinal tympanites, diarrhoea, anus
Door exhaust increases.
Relative to Western medicine, Chinese medicine has more preferable security.In the hypoglycemic that diabetic commonly uses at present into
Medicine includes diabetes pill, diabetes pill, Kelening capsule, JINQI JIANGTANG PIAN etc..Wherein, the composition of diabetes pill
Including：The root of kudzu vine, root of Chinese trichosanthes, glutinous rehmannia, the fruit of Chinese magnoliavine, the tuber of dwarf lilyturf, licorice, there is nourishing Yin and promoting production of body fluid, quench the thirst
Relieving restlessness, QI invigorating and it is middle the effect of.Diabetes pill main component include the root of kudzu vine, root of Chinese trichosanthes, the Radix Astragali, the dried rhizome of rehmannia,
Corn stigma, kadsura longepedunculata, Chinese yam, glibenclamide, major function：Supplementing qi and nourishing yin, nourshing kidney are promoted the production of body fluid, drop
Sugar.But the hypoglycemic curative effect of these Chinese patent drugs fails to reach gratifying effect.Therefore, patient for
The pharmaceutical preparation or health food of hypoglycemic better efficacy there is still a need to.
The content of the invention
In view of this, the invention provides a kind of hypoglycemic composition and preparation method thereof, application.This hair
Bright to be used cooperatively onion oil and grape-kernel oil, onion oil can be played with each lubricant component of grape-kernel oil and cooperateed with
Effect, so as to reach more preferable hypoglycemic effect, effect is used alone better than onion oil or grape-kernel oil
Effect.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The invention provides a kind of vegetable fat composite, including onion oil and grape-kernel oil.
Preferably, the weight of onion oil and grape-kernel oil ratio is 5:1~1:20.
It is highly preferred that the weight of onion oil and grape-kernel oil ratio is 1:1~1:10.
In some embodiments provided by the invention, the weight ratio of onion oil and grape-kernel oil is 5：1.
In other embodiments provided by the invention, the weight ratio of onion oil and grape-kernel oil is 1：1.
In other embodiments provided by the invention, the weight ratio of onion oil and grape-kernel oil is 1：5.
In other embodiments provided by the invention, the weight ratio of onion oil and grape-kernel oil is 1：10.
In other embodiments provided by the invention, the weight ratio of onion oil and grape-kernel oil is 1：20.
Present invention also offers a kind of preparation method of the vegetable fat composite, including：
Step A：After onion is crushed onion oil is obtained through steam distillation；Wherein, steam distillation is
Method well known to those skilled in the art, have no special limitation.
Grape-kernel oil is obtained using milling process after grape pip is crushed；
Step B：Onion oil and grape-kernel oil are mixed, obtain vegetable fat composite.
In embodiment provided by the invention, step A is specially：
After onion is crushed into homogenate, soak, by distillation, obtain onion oil；
Preferably, in terms of g/mL, the ratio of onion and water is 1：(1~10).
Preferably, in terms of g/mL, the ratio of onion and water is 1：(3~7).
It is highly preferred that in terms of g/mL, the ratio of onion and water is 1：(4~6).
In embodiment provided by the invention, in terms of g/mL, the ratio of onion and water is 1：6.
Preferably, the time of distillation is 0.5~6h.
Preferably, the time of distillation is 2~4h.
In embodiment provided by the invention, the time of distillation is 3h.
After grape pip is crushed, by softening, strip plate, stir-fry, squeezing are steamed, obtains grape-kernel oil.
Preferably, softening temperature control is at 60~70 DEG C.
Preferably, moisture control is 10%~15% after softening.
Preferably, the thickness control of base is in 0.4~0.5mm after strip plate.
Preferably, material base moisture is controlled after steaming stir-fry 8%~10%.
Preferably, material base temperature control is at 105~110 DEG C during squeezing, material base thickness control is in 5~6mm.
The active component of onion oil in vegetable fat composite of the present invention is the tool of sulfonylurea butyric acid and sulfur-bearing
There are volatile material, alliin, pi-allyl propyl disulfide compound, the moon bright propylhomoserin sulfoxide (SACS) of S- pi-allyls half
Prevent that insulin is destroyed Deng by redox equilibrium, grape-kernel oil contains abundant linoleic acid, has
Good effect for reducing blood fat, auxiliary hyperglycemic, onion oil act synergistically with each lubricant component of grape-kernel oil,
So as to reach more preferable hypoglycemic effect.Also, onion oil and grape-kernel oil can medicine-food two-purpose, it is no secondary to make
With.
Present invention also offers the vegetable fat composite to prepare hypoglycemic drug or have preventing and treating hyperglycaemia
Application in the health food of function.
Present invention also offers a kind of medicine, including vegetable fat composite provided by the invention.
Preferably, the medicine also includes pharmaceutically acceptable auxiliary material.
Preferably, the formulation of the medicine is granule, capsule, oral agents or syrup.But this hair
Bright pharmaceutical dosage form is not limited to this, and the formulation of those skilled in the art's accreditation is in the scope of the present invention
Within.
Present invention also offers a kind of health food, including vegetable fat composite provided by the invention.
Preferably, the health food also includes acceptable auxiliary material in bromatology.
Preferably, the formulation of the health food be granule, capsule, oral liquid, tablet, pulvis,
Paste, syrup or emulsion.But health food formulation of the present invention is not limited to this, people in the art
The formulation of member's accreditation is within the scope of the present invention.
The invention provides a kind of hypoglycemic composition and preparation method thereof, application.The vegetable fat combines
Thing includes onion oil and grape-kernel oil.The present invention at least has one of following advantage：
1st, onion oil and grape-kernel oil are used cooperatively by the present invention, onion oil and each lubricant component of grape-kernel oil
Synergy can be played, so as to reach more preferable hypoglycemic effect, effect is better than onion oil or grape-kernel oil
The effect of exclusive use；
2nd, onion oil and grape-kernel oil can medicine-food two-purpose, have no side effect；
3rd, the simple science of preparation method of the present invention, can be sufficiently reserved in onion and grape pip grease type effectively into
Point.
Embodiment
The invention discloses a kind of hypoglycemic composition and preparation method thereof, application, those skilled in the art
Present disclosure can be used for reference, is suitably modified technological parameter realization.In particular, it is all similar
Replacement and change it is apparent to those skilled in the art, they are considered as being included in this
Invention.The method of the present invention and application are described by preferred embodiment, and related personnel is obvious
Can do not depart from present invention, method described herein and application are modified in spirit and scope or
Suitably change with combining, to realize and using the technology of the present invention.
Hypoglycemic composition provided by the invention and preparation method thereof, raw materials used, auxiliary material, examination in
Agent etc. can be bought by market.Wherein, the present invention is not particularly limited to the source of all raw materials,
For commercially available or self-control；In following examples, onion oil is that onion obtains through steam distillation, grape
Seed oil obtains for grape pip through squeezing.
With reference to embodiment, the present invention is expanded on further：
The preparation of the hypoglycemic composition of embodiment 1
After onion is crushed, according to onion slurries and water 1g：6ml ratio adds water, is subsequently placed in water steaming
In steam distillation device, heating distillation is untill distillating and not containing oil droplet in moisture, and about distillation time is 3h,
Obtain onion oil.
By grape pip after screening crushes, heating water wetting, heating, softening temperature is controlled at 60~70 DEG C,
Moisture control is 10%~15% after softening；Strip plate, thickness control is in 0.4~0.5mm；Steam and fry base, control
Material base moisture is 8%~10%；Squeezing, at 105~110 DEG C, material base thickness control exists material base temperature control
5~6mm, finally give grape-kernel oil.
The onion oil of 5 parts by weight is mixed with the grape-kernel oil of 1 parts by weight, obtains hypoglycemic composition.
The preparation of the hypoglycemic composition of embodiment 2
The grape that will be obtained in the onion oil obtained in 1 parts by weight of example 1 and 1 parts by weight of example 1
Seed oil mixing, obtains hypoglycemic composition.
The preparation of the hypoglycemic composition of embodiment 3
The grape that will be obtained in the onion oil obtained in 1 parts by weight of example 1 and 5 parts by weight of example 1
Seed oil mixing, obtains hypoglycemic composition.
The preparation of the hypoglycemic composition of embodiment 4
The grape that will be obtained in the onion oil obtained in 1 parts by weight of example 1 and 10 parts by weight of example 1
Seed oil mixing, obtains hypoglycemic composition.
The preparation of the hypoglycemic composition of embodiment 5
The grape that will be obtained in the onion oil obtained in 1 parts by weight of example 1 and 20 parts by weight of example 1
Seed oil mixing, obtains hypoglycemic composition.
The hypoglycemic composition of experimental example 6 has the effect experiment of function of blood sugar reduction
1. experiment purpose
Establish the hyperglycemic rat model of induced by dexamethasone, the hypoglycemic influence to hyperglycemic rat of pre-test.
2. experiment material
2.1 medicines and main agents
(1) main agents
Using the hypoglycemic composition obtained in above-described embodiment 3；Glucose, Anhui Feng Yuan Huai-Hai pharmacy
Co., Ltd；Dexamethasone sodium phosphate injection, Zhengzhou Zhuo Feng pharmaceutical Co. Ltds.
(2) experimental animal
SD rats, male, SPF levels, body weight (150 ± 20) g, by Hubei University of Chinese Medicine's zoopery
The heart provides.
(3) key instrument
Flow cytometer, U.S. company BD；Blood glucose meter：Sure Step Plus System, Johnson
Company；ELIASA：Bio-Rad companies of the U.S.；722 type grating spectrophotometers, Shanghai instrument are total
Factory；Superfreeze refrigerator, U.S. Thermo Fisher Scientific；Electronic analytical balance, BS124S,
German Startorius companies；Ultrapure water machine, Mill-Q II, Milipore, Bedford, MA, USA；
Rat metabolism cage, Suzhou City Feng Laboratory Animal Equipment Co., Ltd；Biological work is built up in kit, Nanjing
Journey research institute.
3. test method
3.1 models are established and pharmaceutical intervention
Rat feeding is in Hubei University of Chinese Medicine's Experimental Animal Center SPF level barrier animals laboratory.Animal
Daily nursing and experiment condition meet《Ministry of Health of the People's Republic of China's experimental animal environment and facility mark
It is accurate》.
Common to maintain material to adapt to raising rat 3~5 days, fasting 3~4 hours takes tail blood, and measure is on an empty stomach
To (0 hour) blood glucose value before glucose, to determining 0.5,2 hour blood glucose after 2.5g/kgBW glucose
Value, as the batch animal basic value.
Model is established：7 groups, i.e. blank control group, model comparison were divided into 0,0.5 hour blood sugar level
Group, 3 sample sets (high dose group, middle dose group and low dose group), 2 single dose group (onion oil lists
Agent group and grape-kernel oil single dose group), every group 15.After each group gives the raising of maintenance material 1 week, model pair
High thermal energy fodder is changed according to group, 3 sample sets and 2 single dose groups, after being fed with 2 weeks, model control group,
3 sample sets and 2 single dose groups give dexamethasone 0.8mg/kgBW respectively on high heat energy feed base
It is injected intraperitoneally (0.008% dexamethasone injection amount 1ml/100g body weight), one time a day, continuous 10 days.
Preventive administration：Blank control group does not process, and 3 sample sets gavages give high, medium and low dosage
Hypoglycemic composition, dosage is followed successively by 370mg/kg.d, 185.0mg/kg.d, 92.5mg/kg.d,
Onion oil and grape-kernel oil single dose group dosage are 185.0mg/kg, and model control group is given in equal volume
Physiological saline, continuous 42 days.
3.2 samples are collected and Indexs measure
Fasting blood-glucose and sugar tolerance (blood sample)：After experiment terminates, each group animal fasting 3~4 hours, tail
Venous blood sampling is used to determine fasting blood-glucose, each group oral administration of glucose 2.5g/kgBW after 15~20 minutes,
Tail vein takes blood when 0.5h and 2h, for determining sugar tolerance.
Insulin, cholesterol, triglyceride, HbAlc are horizontal (blood sample)：After the completion of carbohydrate tolerance test,
Orbital vein takes blood, and separation serum preserves in -80 DEG C of refrigerators.
Liver glycogen, Body development, B cell apoptosis rate (tissue)：After the completion of carbohydrate tolerance test,
Rapid to take out liver and pancreas, -80 DEG C preserve after liver is washed with 0.15MKCI-EDTA solution, and streaming is thin
Born of the same parents' instrument detects B cell apoptosis rate.
Detect each group biochemical indicator respectively using kit, as a result represented with mean ± SD, united using SPSS
Software (12.0) is counted, ANOVA analyses are carried out to result.
4. experimental result
After experiment terminates, the change of each group rat biochemical marker level is shown in Table 1~table 3.
The different group rat sugar tolerances of table 1 compare
Note：#：The p compared with blank group<0.05；##：The p compared with blank group<0.01；*：The p compared with model group<0.05；**：The p compared with model group<0.01.
By the results showed that of table 1 after high lipid food is fed model group rat fasting blood-glucose it is horizontal and
It is more statistically significant with same time point normal diet group rat blood sugar value after 0.5,2.0h after glucose load
(p<0.05), meanwhile, there is area (AUC) the normal group difference that compares under model group glucose curve
Statistical significance (p<0.05).
Fasting blood-glucose is observed, basic, normal, high dosage group, single dose group and model group more have reduction, but
After fasting blood-glucose and glucose load 0.5h, 2.0h, middle and high dosage group has statistics with model group comparing difference
Learn meaning (p<0.05)；Observe fasting blood-glucose, 0.5h, 2h TG-AUC after glucose load, it is high, in,
Low dose group more has significant difference (p with normal group<0.05), with model group more without statistics
Meaning (p>0.05).Illustrate that onion oil and grape-kernel oil composition sample group effect are better than single dose group.
The different group Rat Cholesterols of table 2, triglycerides, insulin, HbAlc compare
Note：#：The p compared with blank group<0.05；##：The p compared with blank group<0.01；*：The p compared with model group<0.05；**：The p compared with model group<0.01.
By results showed that model group rats cholesterol, triglycerides, insulin, the HbAlc of table 2
Significant difference (p is relatively respectively provided with blank group<0.01) modeling success, is prompted.
The cholesterol of sample sets rat, triglycerides, insulin, HbAlc respectively refer to compared with model group
Mark has improvement, and middle and high dosage group difference has significant (p<0.01).Onion oil and grape pip
Fluid composition administration group effect is better than single dose group.
The comparison of table 3 different group rat hepatic glycogen, muscle glycogen, islet beta-cell apoptosis rate
| Group | Number of cases | Muscle glycogen (mg/g) | Hepatic glycogen (mg/g) | Islet beta-cell apoptosis rate (%) |
| Blank group | 15 | 1.001±0.171 | 14.930±1.052 | 1.11±0.12 |
| Model group | 15 | 0.620±0.108## | 7.879±0.441## | 8.70±0.13## |
| Low dose group | 15 | 0.788±0.079* | 11.638±1.001* | 2.70±0.76** |
| Middle dose group | 15 | 0.890±0.099* | 12.669±0.259* | 1.53±0.15** |
| High dose group | 15 | 0.910±0.109* | 13.320±0.558* | 1.31±0.17** |
| Onion oil single dose | 15 | 0.749±0.102* | 9.990±0.199* | 3.12±0.14** |
| Grape-kernel oil single dose | 15 | 0.753±0.072* | 10.661±1.410* | 3.78±0.03** |
Note：#：The p compared with blank group<0.05；##：The p compared with blank group<0.01；*：The p compared with model group<0.05；**：The p compared with model group<0.01.
By results showed that model group rats hepatic glycogen, muscle glycogen, the Intra-islet Apoptosis number of table 3
Amount more has significant difference (p with blank group<0.01) modeling success, is prompted.
Each sample group muscle glycogen, hepatic glycogen are significantly increased, and more have significant difference with model group
(p<0.05)；Islet beta-cell apoptosis rate has decline, more has significant difference with model group
(p<0.01).Onion oil and grape-kernel oil composition sample group effect are better than single dose group.
5. test brief summary
(1) hyperglycemia model rat caused by dexamethasone is directed to, onion oil and grape-kernel oil composition are each
Dosage group is respectively provided with hypoglycemic effect.
(2) found after carrying out group to the effect of each dosage group, middle and high dosage group is to glycolipid generation
Thank that the auxiliary hyperglycemic effect of disorderly rat is more preferable, and there was no significant difference between group.
(3) onion oil and grape-kernel oil composition administration group blood sugar decreasing effect are better than single dose group.
The hypoglycemic composition of embodiment 7 has the effect experiment of function of blood sugar reduction
With reference to the animal experiment method in embodiment 6, respectively with hypoglycemic group of embodiment 1,2,4,5
The hypoglycemic composition of compound alternate embodiment 3 is tested.
Sample sets dosage is 185.0mg/kg.d.
After experiment terminates, the change of each group rat biochemical marker level is shown in Table 4~table 6.
The different proportion composition rat sugar tolerance of table 4 compares
Note：#：The p compared with blank group<0.05,##：The p compared with blank group<0.01,*：The p compared with model group<0.05,**：The p compared with model group<0.01.
Fasting blood-glucose is observed by the results showed that of table 4, each sample group and model group comparing difference without
Statistical significance (p>0.05)；After glucose load 0.5h and 2h, the sample sets of embodiment 1,2,4,5 with
Statistically significant (the p of model group comparing difference<0.05).
The different group Rat Cholesterols of table 5, triglycerides, insulin, HbAlc compare
Note：#：The p compared with blank group<0.05；##：The p compared with blank group<0.01；*：The p compared with model group<0.05；**：The p compared with model group<0.01.
By cholesterol, the glycerine of the sample sets rat of results showed that embodiment 1,2,4,5 of table 5
Compared with model group, difference has significant (p by three esters, insulin, HbAlc<0.05).
The comparison of table 6 different group rat hepatic glycogen, muscle glycogen, islet beta-cell apoptosis rate
| Group | Number of cases | Muscle glycogen (mg/g) | Hepatic glycogen (mg/g) | Islet beta-cell apoptosis rate (%) |
| Blank group | 15 | 1.001±0.171 | 14.930±1.052 | 1.11±0.12 |
| Model group | 15 | 0.620±0.108## | 7.879±0.441## | 8.70±0.13## |
| Embodiment 1 | 15 | 0.776±0.111* | 12.016±0.251* | 2.69±0.34** |
| Sample reality group applies product example group 2 | 15 | 0.863±0.026* | 12.392±0.072* | 1.67±0.27** |
| Embodiment 4 | 15 | 0.877±0.095* | 12.501±0.811* | 1.75±0.47** |
| Embodiment 5 | 15 | 0.810±0.088* | 11.641±1.271* | 2.21±0.11** |
Note：#：The p compared with blank group<0.05；##：The p compared with blank group<0.01；*：The p compared with model group<0.05；**：The p compared with model group<0.01.
It is significantly increased by the results showed that muscle glycogen of table 6, hepatic glycogen, beta Cell of islet withers
Dying rate has decline, and the sample sets rat hepatic glycogen of embodiment 1,2,4,5, muscle glycogen are compared with model group
There is significant difference (p<0.05), the sample sets beta cells of isolated rat islets apoptosis of embodiment 1,2,4,5
Rate more has abnormal significant difference (p with model group<0.01).
Conclusion：As a result show that different ratio onion oil and grape-kernel oil composition show significantly to drop blood
Sugar effect.
Described above is only the preferred embodiment of the present invention, it is noted that for the general of the art
For logical technical staff, under the premise without departing from the principles of the invention, some improvement and profit can also be made
Decorations, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (8)
1. a kind of vegetable fat composite, it is characterised in that including onion oil and grape-kernel oil.
2. vegetable fat composite according to claim 1, it is characterised in that the onion oil with
The weight ratio of the grape-kernel oil is 5:1~1:20.
3. vegetable fat composite according to any one of claim 1 to 2, it is characterised in that
The weight ratio of the onion oil and the grape-kernel oil is 1:1~1:10.
4. the preparation method of vegetable fat composite any one of a kind of claims 1 to 3, it is special
Sign is, including：
Step A：After onion is crushed onion oil is obtained through steam distillation；
Grape-kernel oil is obtained using milling process after grape pip is crushed；
Step B：The onion oil and grape-kernel oil are mixed, obtain vegetable fat composite.
5. preparation method according to claim 4, it is characterised in that the step A is specially：
After onion is crushed into homogenate, soak, by distillation, obtain onion oil；
After grape pip is crushed, by softening, strip plate, stir-fry, squeezing are steamed, obtains grape-kernel oil.
6. vegetable fat composite is preparing hypoglycemic drug any one of a kind of claims 1 to 3
Or the application in the health food with preventing and treating hyperglycaemia function.
7. a kind of medicine, it is characterised in that including vegetable fat any one of claims 1 to 3
Composition.
8. a kind of health food, it is characterised in that including plant any one of claims 1 to 3
Fat or oil composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610371196.4A CN107432904A (en) | 2016-05-27 | 2016-05-27 | A kind of hypoglycemic composition and preparation method thereof, application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610371196.4A CN107432904A (en) | 2016-05-27 | 2016-05-27 | A kind of hypoglycemic composition and preparation method thereof, application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107432904A true CN107432904A (en) | 2017-12-05 |
Family
ID=60458242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610371196.4A Withdrawn CN107432904A (en) | 2016-05-27 | 2016-05-27 | A kind of hypoglycemic composition and preparation method thereof, application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107432904A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110559384A (en) * | 2019-09-11 | 2019-12-13 | 君维安(武汉)生命科技有限公司 | Traditional Chinese medicine prebiotic composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127437A (en) * | 2013-03-01 | 2013-06-05 | 李赤翎 | Traditional Chinese medicine composition having hypoglycemic effect |
| CN105341893A (en) * | 2015-12-08 | 2016-02-24 | 天津元恒德科技有限公司 | Composition for assisting in reducing blood glucose and application |
-
2016
- 2016-05-27 CN CN201610371196.4A patent/CN107432904A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127437A (en) * | 2013-03-01 | 2013-06-05 | 李赤翎 | Traditional Chinese medicine composition having hypoglycemic effect |
| CN105341893A (en) * | 2015-12-08 | 2016-02-24 | 天津元恒德科技有限公司 | Composition for assisting in reducing blood glucose and application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110559384A (en) * | 2019-09-11 | 2019-12-13 | 君维安(武汉)生命科技有限公司 | Traditional Chinese medicine prebiotic composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN101869283A (en) | Assistant hypoglycemia healthcare food of mulberry-leaf extract and preparation method thereof | |
| CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
| CN101411760A (en) | Novel use of plants in sorbus malus group of malus | |
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN103736071B (en) | A kind of composition with auxiliary hyperglycemic effect and application thereof, preparation method | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN101243883B (en) | Health food with function of reducing blood sugar and its preparation | |
| CN102090637A (en) | Collagen-containing compound nutritious powder | |
| CN101283761A (en) | Smallanthus sonchifolius fruit extract and extracting method and application | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN106420955A (en) | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition | |
| CN107432904A (en) | A kind of hypoglycemic composition and preparation method thereof, application | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN107441332A (en) | The ginseng composition and preparation method of auxiliary adjustment endocrine metabolism and anti-cancer and cancer-preventing | |
| CN108904596B (en) | Composition with memory improving effect | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| CN111214641B (en) | Traditional Chinese medicine preparation for treating diabetes | |
| CN109430721A (en) | A kind of wheat embryo composition and preparation method thereof with hypoglycemic effect | |
| CN105533596A (en) | Propolis, radix salviae miltiorrhizae and ginkgo leaf capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171205 |